DNA And Gene Chip Market (2026 - 2033)

DNA & Gene Chip Market Report Summary

The global DNA & gene chip market size was valued at USD 12.6 billion in 2025 and is projected to grow from USD 14.1 billion in 2026 to USD 35.8 billion in 2033, at a CAGR of 14.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of approximately 38.5% in 2025. This growth is attributed to the increasing demand for personalized cancer treatment, advancements in genomic research, and the expanding applications of microarray technology across fields such as agriculture and drug discovery.

In addition, technological innovations in gene expression analysis and the rising prevalence of genetic disorders further contribute to market growth. Several factors fuel the market growth of DNA & gene chips, such as technological developments in robotics, computational capabilities, and microarray fabrication methods.

In addition, microarrays support gene discovery, diagnosis, disease research, and drug development. A DNA chip is an integration of technologies used to concurrently detect the expression levels of at least 10,000 DNA sequences, called genes, using a slide with DNA spots. The increasing adoption of biochips across research and clinical applications is driving demand for DNA microarray technologies. These platforms enable comprehensive genetic profiling and molecular characterization of cancer cells, supporting the identification of tumor biomarkers and the development of targeted treatment strategies. Continuous advancements in microarray instruments and associated technologies are further improving the accuracy, reliability, and efficiency of DNA microarray-based analyses, thereby supporting market growth. In addition, the availability of cost-effective reagents and ancillary products has contributed to the broader adoption of these technologies across research laboratories and clinical settings.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Furthermore, technological innovations, including advances in robotics, computational capabilities, and fabrication methods, have enabled the implementation of DNA microarrays in clinical laboratories. People's growing awareness of early cancer detection is a major driver of growth, as DNA and gene chips are significant for identifying genetic and epigenetic markers in cancer cells. Hence, widespread use in genomics, drug discovery, and gene expression studies continues to boost market growth.

Analyst Perspective

The DNA and gene chip market is expected to witness steady growth, driven by the increasing demand for high-throughput genomic studies, precision medicine, and early disease diagnosis applications. The growing adoption of oligonucleotide and cDNA microarrays across research institutions, hospitals, and biotechnology companies is further supporting market expansion. The market is witnessing rapid technological advancements in microarray platforms, including higher probe density, increased automation, and the integration of artificial intelligence (AI)-enabled bioinformatics tools. These innovations are enhancing the accuracy, speed, and efficiency of genetic analysis across applications such as oncology, chronic disease research, pharmacogenomics, and rare disease screening. Continued technological innovations, expanding clinical applications, and increasing adoption of genomic-based approaches are expected to support sustained market growth over the coming years.

Product Insights

The consumables segment held the largest market share of around 76.0% in 2025, owing to the increased accessibility of various reagents and other aiding components required for executing microarray procedures. Furthermore, this can be associated with cost savings resulting from increased technological advancements and the inception of new equipment with great computing speed that improves the efficacy of microarray procedures.

The instrumentation segment is projected to grow at a notable CAGR over the forecast period. The advancements in microarray technologies, rising demand for high-throughput analysis, enhanced sensitivity and accuracy, more focus on personalized medicine and other diagnostics, as well as increasing demand in data analysis software and bioinformatics tools, all factors together drive the adoption and enhancement of new instrumentation technologies, leading to market growth. Agilent Technologies offers the SureScan Microarray Scanner platform and SurePrint G3 microarray products, which provide high-throughput microarray scanning capabilities and optimized array solutions for genomic research applications. These technologies support DNA hybridization-based analyses and enable researchers to generate high-quality genomic data for applications in genomics and clinical research.

Type Insights

The oligonucleotide DNA microarray segment held the largest revenue share in 2025, driven by several key factors, such as its cost-effectiveness and huge capability for monitoring the expression of each gene in the genome. In addition, it provides several benefits over cDNA microarrays, offering controlled specificity of hybridization and creating a more powerful tool for the analysis of single nucleotide polymorphisms, further escalating the oligonucleotide DNA microarray demand in the market.

The complementary DNA microarray segment is projected to grow significantly over the forecast period. Several key factors are driving the market demand. First, advancements and developments in microarray technology enhance the sensitivity, specificity, and throughput of cDNA microarrays, making them more competent and reliable for different applications. Moreover, the wide use of cDNA microarrays in clinical diagnostics, mainly for cancer profiling, genetic testing, and prenatal screening, fuels the demand.

Application Insights

The cancer diagnosis and treatment segment dominated the market and accounted for the largest revenue share of around 27.0% in 2025, pertaining to the supporting targeted cancer therapies while minimizing the extremely painful biopsies that provide a better patient’s genomic outline. In addition, the increasing prevalence of cancer and the rising demand for personalized therapies enhance the market's appeal. Furthermore, advancements in gene expression technologies and favorable research funding support innovative cancer diagnostics. Genetic chips facilitate a comprehensive understanding of a patient's genomic profile, enabling more effective treatment strategies and targeted therapies, thereby boosting market growth significantly.

The drug discovery segment is projected to grow over the forecast period. Drug Discovery employs gene chips to identify possible drug targets. This growth is driven by the increasing adoption of genomic chip arrays for optimizing traditional drug discovery processes. These chips facilitate disease pathway identification, validation, compound screening, and clinical trials, enhancing efficiency and accuracy in drug development. Furthermore, the rising need for personalized medicine and the growing prevalence of chronic diseases further propel the demand for innovative drug discovery solutions using DNA and gene chips.

End-use Insights

The academic & government research institutes segment held the largest market share of around 69.0% in 2025, attributed to the increasing government and private investments in genomic and technological developments. These institutions use gene chips to study and analyze genetic variations in humans and other organisms. Furthermore, growing partnerships among academic institutions, biotechnology companies, and government initiatives promoting genetic research boost market growth.

The hospitals and diagnostic centers segment is expected to grow at a notable CAGR over the projected years, owing to the increasing adoption of these technologies for early disease detection and personalized treatment. Gene chips enable non-invasive diagnostics, reducing the need for painful procedures such as biopsies. Furthermore, the rising prevalence of genetic disorders and the growing demand for targeted therapies propel the adoption of DNA and gene chips in clinical settings, fueling market expansion in this segment.

Regional Insights

North America DNA and gene chip market dominated the global market with a commanding market share of approximately 38.5% in 2025. This growth is attributed to the rising incidence of different diseases, such as cancer or genetic disorders, in the region. The advantages and multipurpose applications of DNA & gene chips with increasing investment in advanced medical technology for improved results are driving market demand. For instance, in October 2025, Illumina announced the launch of its 5-base sequencing solution in the U.S., enabling simultaneous detection of genetic variation and DNA methylation from a single sample, significantly advancing multiomic analysis capabilities in North America’s genomic research and precision medicine ecosystem.

To learn more about this report, Download Free Sample Report

U.S. DNA And Gene Chip Market Trends

The DNA & chip market in the U.S. dominated the North American market in 2025. This growth is driven by the growing demand in terms of biopharmaceutical research and development for drug discovery, target identification, and biomarker discovery. In addition, the robust expansion of the healthcare industry due to the increasing adoption of DNA microarrays in hospitals for activities such as cancer diagnosis, infectious disease detection, and prenatal genetic screening driven by patient demands and healthcare expenditure, drives the market growth.

Asia Pacific DNA And Gene Chip Market Trends

The Asia Pacific DNA & gene chip market is anticipated to grow at the fastest CAGR over the forecast period. This growth is driven by expanding healthcare expenditures and the rapidly evolving biotechnology industry, with investments from the public and commercial sectors aligned with demand for enhanced and improved results.

The China DNA & gene chip market growth is expected to witness continued expansion over the projected years, driven by the need for precision healthcare and the application of genomics in various fields, including diagnostics, drug discovery, and agriculture.

The Japan DNA & gene chip market is expected to grow substantially, owing to the rising emphasis on precision medicines and augmented demand for personalized medicines. In addition, advancements in healthcare and the use of DNA microarrays in diagnostics have contributed to market growth. Furthermore, the availability of high-tech microarrays, such as sophisticated throughput platforms, better data analysis tools, and automation, enhances performance and competencies.

Europe DNA And Gene Chip Market Trends

The Europe DNA & gene chip market experienced substantial growth over the forecast years. This growth is driven by ongoing technological advancements, expanding DNA and gene chip applications, and rising healthcare investments in the country.

The DNA & gene chip market in the UK is expected to grow significantly, owing to the rising adoption of medical tools and devices in healthcare and increasing demand for quick and precise DNA analysis techniques. In addition, the growing implementation of precision medicine is boosting market growth in the country.

Key DNA And Gene Chip Company Insights

Some of the key companies in the DNA and gene chip market include Thermo Fisher Scientific Inc., Agilent Technologies, Illumina, Inc., Revvity, Arrayit Corporation, Macrogen, Inc., Asper Biotech, CapitalBio Technology Co., Ltd., Greiner Bio-One International GmbH, Microarrays Inc., and Biodiscovery LLC. These companies are focusing on continuous development and innovation to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

• Thermo Fisher Scientific Inc. provides a wide range of innovative technologies, products, and services to its customers. The company’s offerings cater to various industries such as pharmaceuticals, biotechnology, life sciences, diagnostics, and applied markets.

• Revvity, formerly known as PerkinElmer Inc., is a provider of products, services, and solutions for the diagnostics, life sciences, and applied markets. The company offers a wide range of instruments, assay platforms, reagents, and software to support various applications, including cell imaging and analysis, molecular spectroscopy, chromatography, DNA/RNA isolation, in vivo imaging, atomic spectroscopy, and protein analysis and detection.

Key DNA And Gene Chip Companies

The following key companies have been profiled for this study on the DNA & gene chip market:

• Thermo Fisher Scientific Inc.

• Agilent Technologies. Inc

• Illumina, Inc.

• Revvity

• Arrayit Corporation

• Macrogen, Inc.

• Asper Biotech

• CapitalBiotech Co., Ltd.

• Bio-One International GmbH

• Microarrays Inc.,

• Biodiscovery LLC

• Oxford Gene Technology IP Limited

• TOSHIBA HOKUTO ELECTRONICS CORPORATION

• Savyon Diagnostics

• Applied Micro Arrays

• BIOMÉRIEUX

Recent Developments

• In January 2024, Galapagos NV collaborated with Thermo Fisher Scientific to strengthen its distributed CAR-T manufacturing network in the U.S., including the San Francisco area. Under the agreement, Thermo Fisher provided GMP manufacturing and logistics services to support Galapagos’ CAR-T clinical program. The partnership followed an earlier collaboration with Landmark Bio in Boston and aimed to enhance manufacturing capacity and accelerate the delivery of CAR-T therapies to patients.

• In February 2025, Roche introduced Sequencing-by-Expansion (SBX) technology, a novel sequencing platform designed to enable faster and more scalable DNA analysis. The technology is expected to support advancements in next-generation sequencing workflows and genomic research applications.

• In October 2025, Thermo Fisher expanded its Axiom PangenomePro and PharmacoPro arrays, supporting population-scale genotyping, pharmacogenomics research, and disease-related studies through advanced microarray-based genomic analysis.

Global DNA And Gene Chip Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global DNA and gene chip market report based on product, type, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
  • Instrumentation
• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Oligonucleotide DNA Microarrays
  • Complementary DNA Microarrays
  • BAC Clone Chips
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer Diagnosis & Treatment
  • Gene Expression
  • Genotyping
  • Genomics
  • Drug Discovery
  • Agricultural Biotechnology
  • Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic & Government Research Institutes
  • Hospitals and Diagnostics Centers
  • Biotechnology and Pharmaceutical Companies
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait